SVF
Level D· Preclinical EvidenceAnimal Study

Exosome-Infused DTM-MPs Hydrogel Scaffold: A Smart Platform for Tendon Repair with Sustained Bioactivity and Anti-Inflammatory Benefits.

Xu Y., Wu B., Zhang Z., Mai Y., Ling Z., Bian L.

Animal Study on Tendon Injury, Chronic Inflammation, published in ACS Nano (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
ACS Nano (2026)
Country
United States
Reported sample size
—
PMID
41410245
DOI
10.1021/acsnano.5c16275

Abstract (original English)

The regeneration of tendons remains a major challenge in tissue engineering. In this study, we present an original scaffold-based approach for tendon repair that combines decellularized tendon matrix microparticles (DTM-MPs), exosomes derived from human adipose-derived stem/progenitor cells (sub-Exos), and collagen-binding domain (CBD) peptides. This hybrid scaffold (DTM-MPs/CBD@sub-Exos/Gel) was fabricated using a DTM-MPs-based hydrogel to provide sustained release of bioactive exosomes at the site of injury. Characterization of the scaffold revealed high bioactivity, biocompatibility, and enhanced mechanical properties compared to controls. In vitro studies demonstrated that sub-Exos significantly enhanced tendon-specific differentiation of rat tendon-derived mesenchymal stem cells (rTD-MSCs), while CBD modification facilitated controlled exosome release and promoted tendon healing. Macrophage polarization toward the anti-inflammatory M2 phenotype was also favored in the presence of the CBD@sub-Exos-loaded scaffold. In vivo evaluations in a rat Achilles tendon defect model confirmed that the DTM-MPs/CBD@sub-Exos/Gel scaffold accelerated tendon regeneration, restored mechanical properties, and exhibited sustained exosome release. Histological analysis revealed improved tendon matrix formation, with enhanced collagen synthesis and structural alignment in the CBD@sub-Exos-modifi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsHydrogelsExosomesTissue ScaffoldsHumansRatsTendon InjuriesAnti-Inflammatory AgentsMesenchymal Stem CellsTendons
Ankle & FootTendon InjuryChronic Inflammation
View on PubMedDOI

Related research